***Background.*** Tuberculosis is the leading cause of HIV-related morbidity and mortality worldwide. Prevention of TB is one of the essential measures particularly in countries with high burden of both infections. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence, but it is not broadly used. The main objective of the study was to compare the risk of development of tuberculosis among HAART receiving HIV-infected patients who took IPT with those who did not take IPT.

***Methods.*** The study was a secondary analysis of medical record of HIV-infected patients from 2009 to 2012 in east Africa. 836 patients who were enrolled in the HIV care and receiving HAART were included in the study. Patients with a history of Tuberculosis were excluded. The primary exposure of interest was IPT. Six months of Isoniazid drug, to be taken orally, was given to HIV-infected patients after ruling out active Tuberculosis. The primary outcome of interest was incidence of Tuberculosis.

***Results.*** Among the total study population, the cumulative incidence of TB was 5.7/100 person-years. Patients who received IPT had Incidence of Tuberculosis decreased by 85 % (HR = 0.15; 95% CI 0.07, 0.32) compared to those who have not received IPT. Women are less likely to develop tuberculosis than men (HR = 0.64; 95% CI 0.38, 1.06). Compared to patients with baseline WHO stage 1, those with stage 2 (HR = 1.8; 95% CI 0.45, 7.15), stage 3 (HR = 7.2; 95% CI 2.18, 23.46) and stage 4 (HR = 31.1; 95% CI 9.25, 104.57) have higher risk for TB. On a multivariate Cox proportional hazards analysis including IPT, age, sex, WHO stage and CD4 count, the risk for TB has reduced by a 78% (estimated HR = 0.22; 95% CI 0.10, 0.48) among those who took IPT.

***Conclusion.*** The use of IPT among HAART receiving HIV-infected patients is associated with significantly reduced tuberculosis incidence. Developing countries with high burden of TB and HIV should give a high priority in the scaling up of IPT to improve TB control.
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